검색
Telix Pharmaceuticals Ltd
TLX관심 목록에 추가
11.870USD
+0.030+0.25%
종가 07/02, 13:00（ET）시세는 15분 지연됩니다
0.00시가총액
--P/E TTM
자세한 내용은 Telix Pharmaceuticals Ltd 회사
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Telix Pharmaceuticals Ltd 정보
종목 코드 TLX
회사 이름Telix Pharmaceuticals Ltd
상장일Nov 15, 2017
CEOOrtiz (Raphaeel)
직원 수- -
유형Depository Receipt
회계 연도 종료- -
주소55 Flemington Road
도시MELBOURNE
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Australia
우편 번호3051
전화61390933855
웹사이트https://telixpharma.com/
종목 코드 TLX
상장일Nov 15, 2017
CEOOrtiz (Raphaeel)
Telix Pharmaceuticals Ltd의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. David Cade
Dr. David Cade
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Darren Smith, CPA
Mr. Darren Smith, CPA
Group Chief Financial Officer
Group Chief Financial Officer
--
--
Mr. Kevin Richardson
Mr. Kevin Richardson
Chief Executive Officer - Telix Precision Medicine
Chief Executive Officer - Telix Precision Medicine
--
--
Mr. Raphaeel Ortiz
Mr. Raphaeel Ortiz
Chief Executive Officer - Telix International
Chief Executive Officer - Telix International
--
--
Ms. Genevieve Ryan
Ms. Genevieve Ryan
Company Secretary
Company Secretary
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. David Cade
Dr. David Cade
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
자주 묻는 질문
Telix Pharmaceuticals Ltd의 상위 5대 주주는 누구인가요?
Telix Pharmaceuticals Ltd의 상위 5대 주주는 다음과 같습니다: Dr. Christian P. Behrenbruch, J.D., Ph.D.
Telix Pharmaceuticals Ltd(TLX)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Telix Pharmaceuticals Ltd의 주식을 보유한 기관은 총 61곳이며, 이들이 보유한 주식의 총 가치는 약 1.47M로 전체 발행 주식의 0.43%를 차지합니다. 이는 2025Q4 대비 326197.00 증가한 수치입니다.